Primer: Blossomhill Therapeutics (BLSM US) - Aug 2026
Blossomhill Therapeutics is a clinical-stage biopharmaceutical company with a focused pipeline on high-unmet-need oncology indications, led by...
101 Views
BlossomHill Therapeutics (BLSM): IPO Falls Flat After Aggressive Upsizing
​BlossomHill's IPO upsized but opened below issue, BH-30643 key value driver targeting resistant NSCLC, stock closed at IPO price with intraday...
121 Views
BlossomHill Therapeutics (BLSM): Demand Blossoms as Books Near the Finish Line
​Lead candidate BH-30643 targets multiple EGFR mutations in NSCLC, offering a unique opportunity in a field lacking approved targeted therapy....
145 Views
IPO Databook: BlossomHill Therapeutics (BLSM US) - Aug 2026
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer treatment using a...
107 Views
BlossomHill Therapeutics (BLSM) Targets $125 Million IPO to Advance Precision Oncology Pipeline
San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million...
99 Views